EBV BALF2 Genotyping Assays for Higher-Precision NPC Risk Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current serologic and molecular diagnostics for Epstein-Barr Virus (EBV)-associated nasopharyngeal carcinoma (NPC) have low positive predictive value, leading to excessive and costly screening procedures due to false positives, and there is a need for better methods to identify high-risk EBV variants associated with NPC.
Innovation Solution
Genetic profiling using primers and allele-specific probes to detect single nucleotide polymorphisms (SNPs) in the BALF2 gene of EBV, allowing for rapid detection of specific mutations and identifying individuals at high risk of developing NPC through nucleic acid-based diagnostic assays.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If serologic and molecular diagnostics are used for EBV-associated NPC screening, then screening coverage is achieved, but positive predictive value is low due to false positives from benign EBV reactivation
Solution Approach 1:
The patent segments the EBV detection process into multiple stages: initial screening followed by triage testing using nasopharyngeal EBV PCR and plasma EBV next-generation sequencing (NGS). This segmentation allows the system to filter false positives at each stage, improving overall positive predictive value while maintaining screening coverage.
Solution Approach 2:
The patent applies different diagnostic methods with varying specificity to different risk groups and screening stages. High-specificity methods (NGS, PCR) are applied locally to triage positive screens, while broader screening methods are used for initial population screening, optimizing the balance between sensitivity and positive predictive value.
2Reliability
If ancillary triage testing with nasopharyngeal EBV PCR and plasma EBV NGS is performed, then positive predictive value increases, but screening costs and complexity increase
Solution Approach 1:
The patent implements preliminary triage testing with PCR and NGS before committing to expensive and invasive procedures like endoscopies and biopsies. This preliminary action filters out false positives early in the workflow, reducing the burden of complex procedures on patients who do not have true positive cases.
Solution Approach 2:
The patent introduces PCR and NGS as intermediary testing steps between initial serologic screening and definitive diagnostic procedures. These intermediaries provide additional validation layers that improve positive predictive value while avoiding the need to jump directly to complex and invasive procedures.
3Reliability
If ancillary triage testing with nasopharyngeal EBV PCR and plasma EBV NGS is performed, then positive predictive value increases, but screening costs increase
Solution Approach 1:
The patent applies advanced testing (PCR and NGS) partially - only to individuals who screen positive on initial testing, rather than applying it to all screened individuals. This partial application maintains high positive predictive value for the triaged group while controlling overall screening costs.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances the positive predictive value of NPC screening by accurately identifying high-risk individuals, reducing unnecessary procedures and improving treatment outcomes by detecting specific EBV variants associated with NPC.
Implementation Method 1
capable of hybridizing to and amplifying the EBV nucleic acids
Implementation Method 2
allele-specific probes...detecting the presence of one or more alleles at the one or more polymorphisms
Implementation Method 3
amplifying the EBV nucleic acids, if present, with a set of primers
Implementation Method 4
nucleic acid-based diagnostic assays to determine which alleles are present
Data Source
AI summary
Methods and oligonucleotide reagents for genotyping Epstein-Barr virus are disclosed. In particular, genetic profiling is used to detect BALF2 variants in the genome of Epstein-Barr virus in an infected individual to predict the risk of an individual developing nasopharyngeal carcinoma. Primers and allele-specific probes are provided for performing nucleic acid-based diagnostic assays to determine which alleles are present at single nucleotide polymorphisms (SNPs) in the BALF2 gene of Epstein-Barr virus in biological samples from potentially infected subjects. These primers and allele-specific probes can be used for amplifying target sequences to allow rapid detection of a single mutation or multiple mutations in the BALF2 gene simultaneously in a single assay. In addition, methods are provided for identifying individuals at high risk of developing nasopharyngeal carcinoma who are in need of further screening and treatment.